Results 211 to 220 of about 104,757 (302)

Pantoprazole lacks interaction with the NSAID naproxen

, 2000
H.‐U. Schulz, M. Hartmann, Sabine Krupp, M. Schuerer, Reinhard Huber, Reinhold Luehmann, T.D. Bethke, W Wurst   +7 more
openalex   +1 more source

NSAIDs and gut toxicity

The Lancet, 1994
H. M. Pearce, H. M. Pearce, P.M. Bennett, P.M. Bennett, D. G. Grahame-Smith, D. G. Grahame-Smith, CharlesM. Grossman, David Reynolds, David Reynolds, Jeffrey K Aronson, Jeffrey K Aronson, Catherine C. Smith, Catherine C. Smith   +12 more
openaire   +3 more sources

Effect of parecoxib on postoperative cognitive function and analgesic safety in elderly patients undergoing gastrointestinal tumor resection: A retrospective study. [PDF]

Biomol Biomed
Li Y, Peng Y.
europepmc   +1 more source

Decision analytic modeling and NSAID gastropathy could we be more sensitive?

, 2000
A. Mark Fendrick, James M. Scheiman
openalex   +2 more sources

The Effect of NSAID Use on Dextrose Prolotherapy in Patients With Knee Osteoarthritis: A Prospective Case Series. [PDF]

Clin Med Insights Arthritis Musculoskelet Disord
Kim AR, McNeary-Garvin A, Thornton JA, Covey CJ.   +3 more
europepmc   +1 more source

JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management

United European Gastroenterology Journal, EarlyView.
ABSTRACT JAK inhibitors are pivotal in treating immune‐mediated inflammatory diseases (IMIDs) like rheumatoid arthritis (RA) and inflammatory bowel disease. However, emerging safety concerns warrant careful evaluation. A recent analysis of the FDA Adverse Event Reporting System (FAERS) revealed that RA patients using JAK inhibitors face nearly double ...
Luisa Bertin, Edoardo Vincenzo Savarino
wiley   +1 more source

Presence of gluten and soy derived excipients in medicinal products and their implications on allergen safety and labeling. [PDF]

Sci Rep
Figueiredo A, Auxtero MD, Brás A, Casimiro A, Costa IM.   +4 more
europepmc   +1 more source

Celecoxib is associated with a lower incidence of serious GI toxicity relative to nonsteroidal anti-inflammatory drugs (NSAIDs)

, 2000
JL Goldstein
openalex   +1 more source

Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background Gastrointestinal perforations have been reported in a small number of rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors in clinical trials. However, large‐scale postmarketing data repositories are needed to further investigate this potentially rare but serious adverse event.
Adam Goldman, Emanuel Raschi, Amit Druyan, Kassem Sharif, Adi Lahat, Ilan Ben‐Zvi, Shomron Ben‐Horin   +6 more
wiley   +1 more source

Assessment of the proportion of gastrointestinal perforations, ulcers and bleeds (PUBS) attributable to NSAIDs

, 2000
Walter L. Straus, Joshua J. Ofman, Catherine H. MacLean, Sally C. Morton, Elizabeth Röth, Marc Berger, Paul Shekelle   +6 more
openalex   +1 more source